Terms: = Prostate cancer AND RHOA, ENSG00000067560, 387, ARHA, RhoA, RHOH12, RHO12, ARH12, Rho12 AND Prognosis
19 results:
1. MYBL2 disrupts the Hippo-YAP pathway and confers castration resistance and metastatic potential in prostate cancer.
Li Q; Wang M; Hu Y; Zhao E; Li J; Ren L; Wang M; Xu Y; Liang Q; Zhang D; Lai Y; Liu S; Peng X; Zhu C; Ye L
Theranostics; 2021; 11(12):5794-5812. PubMed ID: 33897882
[No Abstract] [Full Text] [Related]
2. Waist circumference and a body shape index and prostate cancer risk and mortality.
Jochems SHJ; Wood AM; Häggström C; Orho-Melander M; Stattin P; Stocks T
Cancer Med; 2021 Apr; 10(8):2885-2896. PubMed ID: 33710775
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic significance of total plasma cell-free DNA level and androgen receptor amplification in castration-resistant prostate cancer.
Kubota Y; Hatakeyama S; Yoneyama T; Yoneyama MS; Hamano I; Konishi S; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Ohyama C
World J Urol; 2021 Sep; 39(9):3265-3271. PubMed ID: 33675416
[TBL] [Abstract] [Full Text] [Related]
4. External validation of life expectancy prognostic models in patients evaluated for palliative radiotherapy at the end-of-life.
Mojica-Márquez AE; Rodríguez-López JL; Patel AK; Ling DC; Rajagopalan MS; Beriwal S
Cancer Med; 2020 Aug; 9(16):5781-5787. PubMed ID: 32592315
[TBL] [Abstract] [Full Text] [Related]
5. The Identification of Key Gene Expression Signature in prostate cancer.
Huang Y; Cao Q; Song Z; Ruan H; Wang K; Chen K; Zhang X
Crit Rev Eukaryot Gene Expr; 2020; 30(2):153-168. PubMed ID: 32558494
[TBL] [Abstract] [Full Text] [Related]
6. Microarray-based data mining reveals key genes and potential therapeutic drugs for Cadmium-induced prostate cell malignant transformation.
Xiang Y; Zhang L; Huang Y; Ling J; Zhuo W
Environ Toxicol Pharmacol; 2019 May; 68():141-147. PubMed ID: 30897525
[TBL] [Abstract] [Full Text] [Related]
7. Survival analysis of malignant epidural spinal cord compression after palliative radiotherapy using Tokuhashi scoring system and the impact of systemic therapy.
Mui WH; Lam TC; Wong FCS; Sze WK
Ann Palliat Med; 2017 Dec; 6(Suppl 2):S132-S139. PubMed ID: 29156895
[TBL] [Abstract] [Full Text] [Related]
8. Diaphanous-related formin-3 overexpression inhibits the migration and invasion of triple-negative breast cancer by inhibiting rhoa-GTP expression.
Jiang J
Biomed Pharmacother; 2017 Oct; 94():439-445. PubMed ID: 28779705
[TBL] [Abstract] [Full Text] [Related]
9. Genetic variants in rhoa and ROCK1 genes are associated with the development, progression and prognosis of prostate cancer.
Liu K; Li X; Wang J; Wang Y; Dong H; Li J
Oncotarget; 2017 Mar; 8(12):19298-19309. PubMed ID: 28184030
[TBL] [Abstract] [Full Text] [Related]
10. Small-Molecule Protein-Protein Interaction Inhibitor of Oncogenic Rho Signaling.
Diviani D; Raimondi F; Del Vescovo CD; Dreyer E; Reggi E; Osman H; Ruggieri L; Gonano C; Cavin S; Box CL; Lenoir M; Overduin M; Bellucci L; Seeber M; Fanelli F
Cell Chem Biol; 2016 Sep; 23(9):1135-1146. PubMed ID: 27593112
[TBL] [Abstract] [Full Text] [Related]
11. Diabetes and cancer: a Review of Current Knowledge.
Wojciechowska J; Krajewski W; Bolanowski M; Kręcicki T; Zatoński T
Exp Clin Endocrinol Diabetes; 2016 May; 124(5):263-75. PubMed ID: 27219686
[TBL] [Abstract] [Full Text] [Related]
12. Unbiased estimates of long-term net survival of solid cancers in France.
Jooste V; Grosclaude P; Remontet L; Launoy G; Baldi I; Molinié F; Arveux P; Bossard N; Bouvier AM; Colonna M;
Int J Cancer; 2013 May; 132(10):2370-7. PubMed ID: 23001495
[TBL] [Abstract] [Full Text] [Related]
13. Protein kinase A-mediated phosphorylation of rhoa on serine 188 triggers the rapid induction of a neuroendocrine-like phenotype in prostate cancer epithelial cells.
Jones SE; Palmer TM
Cell Signal; 2012 Aug; 24(8):1504-14. PubMed ID: 22504159
[TBL] [Abstract] [Full Text] [Related]
14. prostate size as a predictor of Gleason score upgrading in patients with low risk prostate cancer.
Davies JD; Aghazadeh MA; Phillips S; Salem S; Chang SS; Clark PE; Cookson MS; Davis R; Herrell SD; Penson DF; Smith JA; Barocas DA
J Urol; 2011 Dec; 186(6):2221-7. PubMed ID: 22014803
[TBL] [Abstract] [Full Text] [Related]
15. Genome-wide association study identifies a genetic variant associated with risk for more aggressive prostate cancer.
FitzGerald LM; Kwon EM; Conomos MP; Kolb S; Holt SK; Levine D; Feng Z; Ostrander EA; Stanford JL
Cancer Epidemiol Biomarkers Prev; 2011 Jun; 20(6):1196-203. PubMed ID: 21467234
[TBL] [Abstract] [Full Text] [Related]
16. Urotensin II receptor predicts the clinical outcome of prostate cancer patients and is involved in the regulation of motility of prostate adenocarcinoma cells.
Grieco P; Franco R; Bozzuto G; Toccacieli L; Sgambato A; Marra M; Zappavigna S; Migaldi M; Rossi G; Striano S; Marra L; Gallo L; Cittadini A; Botti G; Novellino E; Molinari A; Budillon A; Caraglia M
J Cell Biochem; 2011 Jan; 112(1):341-53. PubMed ID: 21080343
[TBL] [Abstract] [Full Text] [Related]
17. EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients.
Laitinen S; Martikainen PM; Tolonen T; Isola J; Tammela TL; Visakorpi T
Int J Cancer; 2008 Feb; 122(3):595-602. PubMed ID: 17943722
[TBL] [Abstract] [Full Text] [Related]
18. Perineural invasion and Gleason 7-10 tumors predict increased failure in prostate cancer patients with pretreatment PSA <10 ng/ml treated with conformal external beam radiation therapy.
Anderson PR; Hanlon AL; Patchefsky A; Al-Saleem T; Hanks GE
Int J Radiat Oncol Biol Phys; 1998 Jul; 41(5):1087-92. PubMed ID: 9719119
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic factors in pTa-pT1 superficial bladder tumours treated with intravesical instillations. The Dutch South-Eastern Urological Collaborative Group.
Mulders PF; Meyden AP; Doesburg WH; Oosterhof GO; Debruyne FM
Br J Urol; 1994 Apr; 73(4):403-8. PubMed ID: 8199828
[TBL] [Abstract] [Full Text] [Related]
